Literature DB >> 2140127

Immunoconjugates containing ricin A chain and either human anti-gp41 or CD4 kill H9 cells infected with different isolates of HIV, but do not inhibit normal T or B cell function.

M A Till1, V Ghetie, R D May, P C Auerbach, S Zolla-Pazner, M K Gorny, T Gregory, J W Uhr, E S Vitetta.   

Abstract

We have previously reported that immunoconjugates composed of deglycosylated ricin A chain coupled to either recombinant (r) CD4 or two different monoclonal human anti-gp41 antibodies (rCD4-dgA and anti-gp41-dgA, respectively) are specifically toxic to HIV-infected lines of human T cells (H9) and monocytes (U937). In order to further evaluate these immunoconjugates as potential therapeutic reagents for killing HIV-infected cells, H9 cells infected with five different isolates of HIV were used as target cells in vitro. All three HIV-specific immunoconjugates were toxic to H9 cells infected with each HIV isolate, but were virtually nontoxic to uninfected cells. Chloroquine markedly potentiated the specific toxicity of all three conjugates, particularly the anti-gp41-dgAs. None of the conjugates affected the ability of normal peripheral blood B cells to respond to mitogen or the ability of normal T cells to respond to alloantigens.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2140127

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  4 in total

1.  Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies.

Authors:  J Y Xu; M K Gorny; T Palker; S Karwowska; S Zolla-Pazner
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

2.  N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.

Authors:  Ruth A McCaffrey; Cheryl Saunders; Mike Hensel; Leonidas Stamatatos
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

3.  Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins.

Authors:  Ekaterina Dadachova; Mahesh C Patel; Sima Toussi; Christos Apostolidis; Alfred Morgenstern; Martin W Brechbiel; Miroslaw K Gorny; Susan Zolla-Pazner; Arturo Casadevall; Harris Goldstein
Journal:  PLoS Med       Date:  2006-11       Impact factor: 11.069

4.  Modulation of the splicing regulatory function of SRSF10 by a novel compound that impairs HIV-1 replication.

Authors:  Lulzim Shkreta; Marco Blanchette; Johanne Toutant; Emmanuelle Wilhelm; Brendan Bell; Benjamin A Story; Ahalya Balachandran; Alan Cochrane; Peter K Cheung; P Richard Harrigan; David S Grierson; Benoit Chabot
Journal:  Nucleic Acids Res       Date:  2017-04-20       Impact factor: 16.971

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.